Phase 2 Startpositive

Phase 2 Start: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmen

Name: Phase 2 Start: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmen
Start: 2026-07-07
End: 2026-07-07

July 7, 2026

Company: National Research Corporation Common Stock (Delaware) (NRC)
Drug: n-acetyl-d-mannosamine
Indication: Focal Segmental Glomerulosclerosis

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 2 Start: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmen — NRC Phase 2 Start | BioSniper